StocksUpdated×2•Originally published 21 May 2026•Updated 22 May 2026•
1 min read

Copart Q3 Revenue Beats Estimates at $1.24B as Buybacks Support EPS Growth

Key Facts

1Copart reported Q3 2026 revenue of $1.2 billion, representing a 2.1% year-over-year increase.
2Fully diluted earnings per share rose 2.4% to $0.43, despite a 1.0% decrease in net income.
3Common stock repurchases supported diluted EPS growth during the first nine months of the fiscal year.

Copart reported its fiscal Q3 2026 financial results, with revenue reaching $1.24 billion, surpassing FactSet analyst estimates of $1.19 billion. Fully diluted earnings per share rose 2.4% to $0.43, even as net income experienced a marginal 1.0% decrease. According to reports, the growth in EPS was primarily supported by common stock repurchases conducted during the first nine months of the fiscal year.

This revenue beat of approximately 4% distinguishes Copart from peers in the vehicle auction sector, where organic growth has faced headwinds. Competitors such as IAA Holdings and Ritchie Bros have navigated margin pressures amid fluctuating auction volumes, per market data. Analysts noted that the combination of top-line outperformance and strategic share buybacks has bolstered investor confidence relative to industry averages (per Reuters financial data).

Moving forward, investors are focusing on the sustainability of buyback programs as a primary catalyst for CPRT stock. On the economic calendar, the upcoming NY Empire State Manufacturing Index (scheduled for May 15, 2026) will be monitored for broader industrial health signals that impact vehicle processing volumes. Market participants will watch if the company can transition from buyback-driven EPS growth to organic net income recovery in the final quarter of the fiscal year.

Latest Updates · 1

  1. Notable·

    Update: Eight analysts have lowered Copart's average 12-month price target from $42.38 to $41.62, a downward adjustment of approximately 1.8%. Despite the lower target, the consensus among 15 analysts remains a 'Buy,' supported by 9 buy ratings, 5 holds, and 1 sell, indicating continued institutional confidence in the stock's upside potential.